Structural changes in the Russian pharmaceutical market of anti-tb drugs

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


In Russia, the epidemic situation for tuberculosis has stabilized with a tendency to improvement, according to the dynamics of the main indicators for the disease. However, the problem of tuberculosis infection is still far from being resolved, which is largely due to the development of drug resistance of the infectious agent to the main anti-TB drugs.

The purpose of the study is to form macro-structures of the Russian market of anti-TB drugs for 2008 and 2018 and analyze the dynamics of their structural changes.

Materials and methods. The State registers of medicines of the Russian Federation for 2008 and 2018 were analyzed. Into account were taken following characteristics of the range: the number of registered anti-TB drugs, dosage forms, dosages, manufacturers, and the number of combined anti-TB drugs. The necessary data was obtained using the content analysis method. The results of the study allowed us to build macro-structures of the Russian market of anti-TB drugs and compare the indicators in the dynamics over 10 years.

Results. Over the past 10 years, about 500 anti-TB drugs have been registered and re-registered in the Russian Federation. The range of the selected segment was supplemented by the 3rd new series, which according to 2018 included 166 (30.0%) drugs, taking into account all dosage forms and dosages. The group of anti-TB drugs of the 2nd series in 2018 was the leader in the selected segment (52.2%) and there was a tendency for its growth. In the structure of the assortment of medicinal forms of anti-TB drugs, tablet drugs prevailed (43.5%). The production vector has shifted towards domestic manufacturers. The share of new drugs put into circulation in 2008-2018 was 37%. The nomenclature of the Russian anti-TB market corresponds to international recommendations and contains the main groups of drugs.

Conclusion. Analysis of the segment of anti-TB drugs in the domestic pharmaceutical market showed that the phthisiological service has a sufficient range of drugs for the treatment of tuberculosis infection, including those with drug resistance of the pathogen. This allows to personalize therapy based on the stage and severity of the disease, the functional characteristics of the patient’s body, and the sensitivity of the pathogen to chemotherapy.


Full Text

Restricted Access

About the authors

Natalia E. Usacheva

Smolensk State Medical University

Author for correspondence.
Email: nataly09ka@yandex.ru

Russian Federation, Smolensk

Assistant of the Pharmacology Department

Vasiliy E. Novikov

Smolensk State Medical University

Email: novikov.farm@yandex.ru

Russian Federation, Smolensk

Doctor of Medical Sciences, Professor, Head of the Pharmacology Department

Tatyana V. Myakisheva

Smolensk State Medical University

Email: tatya-myakisheva@yandex.ru

Russian Federation, Smolensk

Doctor of Medical Sciences, Associate Professor, Head of the Phthisiopulmonology Department

Nadezhda A. Pavluchenkova

Smolensk State Medical University

Email: paramonovanadezhda@gmail.com

Russian Federation, Smolensk

Candidate of Pharmaceutical Sciences, Associate Professor, Department of Management and Economy of Pharmacy

Elena V. Trun

Smolensk State Medical University

Email: elena.trun@mail.ru

Russian Federation, Smolensk

Assistant of the Phthisiopulmonology Department

References

  1. Аксенова-Сорахтей Ю.Н., Новиков В.Е., Пожилова Е.В., и др. Фармацевтические и юридические аспекты фальсификации лекарственных средств // Вестник Смоленской государственной медицинской академии. – 2016. – Т. 15. – № 2. – С. 102–111. [Aksenova-Sorokhtey JN, Novikov VE, Pozhilova EV, et al. Pharmaceutical and legal aspects of falsification of medicines. Bulletin of the Smolensk state medical Academy. 2016;15(2): 102-111. (In Russ.)]
  2. Галкин В.Б., Мушкин А.Ю., Муравьев А.Н., и др. Половозрастная структура заболеваемости туберкулезом различных локализаций в Российской Федерации: динамика в XXI в // Туберкулёз и болезни лёгких. – 2018. – Т. 96. – № 11. – С. 17–26. [Galkin VB, Mushkin AYu, Muraviev AN, et al. The gender and age structure of the incidence of tuberculosis (various localizations) in the Russian Federation: changes over the XXIth century. Tuberculosis and Lung Diseases. 2018;96(11):17-26. (In Russ.)] https://doi.org/10.21292/2075-1230-2018-96-11-17-26.
  3. Всемирная организация здравоохранения. Доклад о глобальной борьбе с туберкулезом. Женева: ВОЗ, 2019. [World Health Organization. Doklad o global’noy bor’be s tuberkulezom. Geneva: WHO; 2019. (In Russ.)]
  4. Мохирева Л.В., Хосева Е.Н., Каркач О.О., и др. Фармакоэпидемиологическое исследование воспроизведенных комбинированных противотуберкулезных препаратов и приверженности к ним врачей-фтизиатров в широкой клинической практике // Биомедицина. – 2011. – № 3. – С. 141–148. [Mokhireva LV, Khoseva EN, Karkach OO, et al. Pharmakoepidemiology research of the reproduced combined antitubercular preparations and adherence to them of phthisiatricians in wide clinical practice. Biomeditsina. 2011;(3):141-148. (In Russ.)]
  5. Нечаева О.Б. Эпидемическая ситуация по туберкулезу в России // Туберкулез и болезни легких. – 2018. – Т. 96. – № 8. – С. 15–24. [Nechaeva OB. Epidemic situation of tuberculosis in Russia. Tuberculosis and Lung Diseases. 2018;96(8):15-24. (In Russ.)] https://doi.org/10.21292/2075-1230-2018-96-8-15-24.
  6. Нечаева О.Б. Социально значимые инфекционные заболевания, представляющие биологическую угрозу населению России // Туберкулез и болезни легких. – 2019. – Т. 97. – № 11. – С. 7–17. [Nechaeva OB. Socially important infectious diseases posing a biological threat to the population of Russia. Tuberculosis and Lung Diseases. 2019;97(11):7-17. (In Russ.)]. https://doi.org/10.21292/2075-1230-2019-97-11-7-17.
  7. Новиков В.Е., Климкина Е.И. Фармакология гепатопротекторов // Обзоры по клинической фармакологии и лекарственной терапии. – 2005. – Т. 4. – № 1. – С. 2–20. [Novikov VE, Klimkina EI. Pharmacology of hepatoprotectors. Reviews on Clinical Pharmacology and drug therapy. 2005;4(1):2-20. (In Russ.)]
  8. Новиков В.Е., Левченкова О.С., Пожилова Е.В. Роль активных форм кислорода в физиологии и патологии клетки и их фармакологическая регуляция // Обзоры по клинической фармакологии и лекарственной терапии. – 2014. – Т. 12. – № 4. – С. 13–21. [Novikov VE, Levchenkova OS, Pozhilova EV. Role of reactive oxygen species in cell physiology and pathology and their pharmacological regulation. Reviews on Clinical Pharmacology and Drug Therapy. 2014;12(4):13-21. (In Russ.)]. https://doi.org/10.17816/RCF12413-21.
  9. Новиков В.Е., Лосенкова С.О. Фармакология производных 3-оксипиридина // Обзоры по клинической фармакологии и лекарственной терапии. – 2004. – Т. 3. – № 1. – С. 2–14. [Novikov VE, Losenkova SO. Pharmacology of 3-hydroxypyridine derivatives. Reviews on Clinical Pharmacology and Drug Therapy. 2004;3(1): 2-14. (In Russ.)]
  10. Новикова А.В., Пожилова Е.В., Новиков В.Е. Лекарственные взаимодействия в структуре осложнений фармакотерапии // Смоленский медицинский альманах. – 2018. – № 3. – С. 14–17. [Novikova AV, Pozhilova EV, Novikov VE. Drug interactions in the structure of pharmacotherapy complications. Smolenskiy meditsinskiy almanakh. 2018;(3):14-17. (In Russ.)]
  11. Приказ Минздрава РФ № 951 от 29 декабря 2014 г. Об утверждении методических рекомендаций по совершенствованию диагностики и лечения туберкулеза органов дыхания. [Order of the Ministry of Health of the Russian Federation № 951 of 2014 Dec 29. Ob utverzhdenii metodicheskikh rekomendatsiy po sovershenstvovaniyu diagnostiki i lecheniya tuberkuleza organov dykhaniya. (In Russ.)]
  12. О совершенствовании противотуберкулезных мероприятий в Российской Федерации: Приказ Минздрава РФ № 109 от 21 марта 2003 г. (в ред. от 29 окт. 2009 г.). [Order of the Ministry of Health of the Russian Federation № 109 of 2003 Mar 21 (edited 2009 Oct 29). O sovershenstvovanii protivotuberkuleznykh meropriyatiy v Rossiyskoy Federatsii. (In Russ.)]
  13. Поддубная Л.В., Дубакова Г.Ф., Литвинова И.А., и др. Оптимизация лечения туберкулеза у детей старшего возраста и подростков / Тезисы VI Всероссийской научно-практической конференции «Актуальные вопросы профилактики, диагностики и лечения туберкулеза у детей и подростков»; Сочи, 29–31 марта 2018 г. – Сочи, 2018. [Poddubnaya LV, Dubakova GF, Litvinova IА, et al. Optimizatsiya lecheniya tuberkuleza u detey starshego vozrasta i podrostkov. In: Proceedings of the 6th All-Russian scientific and practical conference “Аktualnye voprosy profilaktiki, diagnostiki i lecheniya tuberkuleza u detey i podrostkov”; Sochi, 29–31 Mar 2018. Sochi; 2018. (In Russ.)]
  14. Суслов Н.И., Добрусина М.Е., Чурин А.А., Лосев Е.А. Фармацевтический маркетинг: учебное пособие для бакалавриата и магистратуры. – М.: Юрайт, 2018. – 319 с. [Suslov NI, Dobrusina ME, Churin AA, Losev EA. Farmatsevticheskiy marketing: uchebnoye posobiye dlya bakalavriata i magistratury. Moscow: Yurayt; 2018. 319 p. (In Russ.)]
  15. Фтизиатрия. Национальное руководство / под ред. М.И. Перельмана. – М.: ГЭОТАР-Медиа, 2007. – 512 с. [Ftiziatriya. Natsional’noe rukovodstvo. Ed. M.I. Perel’mana. Moscow: GEOTAR-Media; 2007. 512 p. (In Russ.)]
  16. World Health Organization. Treatment of tuberculosis. Guidelines. 4th ed. Geneva: WHO; 2010.

Statistics

Views

Abstract - 55

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2020 Usacheva N.E., Novikov V.E., Myakisheva T.V., Pavluchenkova N.A., Trun E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies